| MIRACLE I | CeloNova BioSciences, Inc. | Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma (MIRACLE I) | 3 | HCC | palliative therapy, locally advanced |
| CA209-040 | BMS | A Phase I Dose Escalation Study of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma | 1/2 | HCC | palliative therapy, first line |
| CIDH305X2101 | Novartis | IDH305 for patients with relapsed glioma, AML or CC with IDH1-mutated | 1 | CC | palliative second line |
| Oncosorb | BioPheresis GmbH | Clinical Study of OncoSorb® in Patients With Advanced Cancer Entities (BP-005) | 1 | HCC | palliative therapy, last-line (solid tumors) |
| AMG 386 | amgen | A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer | 2 | HCC | palliative therapy, first line |
| HeiLivCa | IIT | TACE +/- Sorafenib | 3 | HCC | neoadjuvant therapy before LTx |
| CetuGEX | Glycotope GmbH | CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer (RESGEX) | 1 | HCC | palliative therapy last-line (solid tumors) |
| SHELTER | | Phase II trial evaluating resminostat in advanced hepatocellular carcinoma (HCC) | 2 | HCC | palliative therapy, second line (after Sorafenib) |
| GATHER | Roche | A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | 2 | HCC | palliative therapy, second line (after Sorafenib) |
| BIBF 1120 | Boehringer-Ingelheim | Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | 1/2 | HCC | palliative therapy, first line |
| INSIGHT | Bayer | INSIGHT - Post Marketing Surveillance (INSIGHT) | 4 | HCC | palliative therapy, first line |
| SPACE | Bayer | A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). | 3 | HCC | locally advanced |
| SOCS | MedImmune LLC | MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. (MEDI-573-1028) | 2 | HCC | palliative therapy, first line |
| TRAVERSE | Jenerex | A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib (TRAVERSE) | 2b | HCC | palliative therapy, second line (after Sorafenib) |
| BAY86-9766 | Bayer | Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) | 2 | HCC | palliative therapy, Kras-mutated patients |
| PICCA | IIT | Cis/Gem vs. CIS/Gem + Panitumumab | | CC | |
| ARQ197-A-U303 | DAIICHI SANKYO PHARMA | Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy (METIV-HCC) | 3 | HCC | palliative therapy, second line (after Sorafenib) |
| E7080-G000-304 | Eisai | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma | 3 | HCC | palliative therapy, first line |
| CBGJ398X2204 | Novartis | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | 1/2 | CC | palliative therapy, second line, with genetic FGFR-alteration |
| BAY86-9766 | Bayer | Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) | 2 | HCC | palliative therapy, first line, Kras-mutated patients |
| Resorce | Bayer | Study with Regorafenib for patients with advanced HCC after Sorafenib | 3 | HCC | palliative therapy, second line (after Sorafenib) |
